Who is sponsoring NCT07331857?

NCT07331857 is sponsored by Digma Medical Ltd..

What drugs are being tested in NCT07331857?

Interventions in NCT07331857: Endoscopic Gastrointestinal Ablation Device (EGAD).

What condition does NCT07331857 study?

NCT07331857 studies Barrett's Esophagus (BE).

Is NCT07331857 still recruiting?

NCT07331857 is currently not yet recruiting. Last updated 12 January 2026.

Last reviewed 2026-01-12 · How we verify

NCT07331857

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Digma System First in Human (FIH) Study

Not yet recruiting NA Last updated 12 January 2026

What this trial tests

NA trial testing Endoscopic Gastrointestinal Ablation Device (EGAD) in Barrett's Esophagus (BE) in 20 participants. Not yet recruiting.

Timeline

1 January 2026

Primary endpoint
31 December 2026

31 December 2027

Quick facts

Lead sponsor	Digma Medical Ltd.
Phase	NA
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	1 January 2026
Primary completion	31 December 2026
Estimated completion	31 December 2027
Sites	1 location across Czechia

Drugs / interventions tested

Endoscopic Gastrointestinal Ablation Device (EGAD)

Conditions studied

Barrett's Esophagus (BE) — all drugs for Barrett's Esophagus (BE) →

Sponsor

Digma Medical Ltd.

Who can join

Adults 18 to 70, any sex, with Barrett's Esophagus (BE). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Prospective, open-label, single-arm, early feasibility study (EFS) in 2 Patient cohorts: Cohort A - Dose finding / Dose response study in patients with various etiologies undergoing Esophagectomy and Cohort B - Patients with Barrett's Esophagus (BE) with Low-Grade Dysplasia (LDG) or High-Grade Dysplasia (HGD) without a visible (excisable) lesion. This is a pilot study which plan to enroll up to 5 eligible patients in the First Cohort (A) and up to 15 patients in the Second Cohort (B) of the study.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Digma Medical Ltd. trials

Trials by the same sponsor.

NCT03390322 — Safety and Initial Performance of the DiaGone Device on Type 2 Diabetes Patients · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07331857 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Digma Medical Ltd.
Last refreshed: 12 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07331857.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing